Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28455795 | 1.00 | CA12 (0.33) | CA12CA1CA2MMP1MMP2 | |
| Cyclopentene SCHEMBL7793202 | 0.87 | CA12 (0.30) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL5146947 | 0.84 | MMP1 (0.35) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL27746065 | 0.83 | KDM4E (0.30) | — | |
| SCHEMBL12503916 | 0.83 | KDM4E (0.30) | — | |
| SCHEMBL10004949 | 0.81 | CA12 (0.35) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL29852867 | 0.81 | CA12 (0.33) | CA12CA1CA2MMP1MMP2 | |
| SCHEMBL21052575 | 0.80 | MMP1 (0.31) | MMP1MMP2 | |
| SCHEMBL17818353 | 0.80 | MMP1 (0.31) | MMP1MMP2 | |
| SCHEMBL7797032 | 0.79 | TAS1R3 (0.37) | MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040126-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2008131501-A2 | NEW ANTI-VIRAL NUCLEOSIDE ANALOGS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2008-11-06 | — | — | WO | disclosed |
| US-6482805-B2 | AZT derivatives exhibiting spermicidal and anti-viral activity | PARKER HUGHES INSTITUTE | 2002-11-19 | — | — | US | disclosed |
| US-6407078-B1 | THYMINE RING (E.G. AZIDOTHYMIDINE, AZT) THAT HAS 5-HALO, 6-ALKOXY SUBSTITUTION | PARKER HUGHES INSTITUTE | 2002-06-18 | — | — | US | disclosed |
| EP-1202749-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | Newbiotics, Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| US-20020025922-A1 | AZT derivatives exhibiting spermicidal and anti-viral activity | UCKUN, FATIH M. | 2002-02-28 | — | — | US | disclosed |
| US-20020022600-A1 | AZT DERIVATIVES EXHIBITING SPERMICIDAL AND ANTI-VIRAL ACTIVITY | UCKUN, FATIH M. | 2002-02-21 | — | — | US | disclosed |
| EP-1117669-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) | 2001-07-25 | — | — | EP | disclosed |
| US-6191120-B1 | CONTRACEPTIVE; VIRICIDE | WAYNE HUGHES INSTITUTE | 2001-02-20 | — | — | US | disclosed |
| WO-2001007087-A2 | ENZYME CATALYZED ANTI-INFECTIVE THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 2001-02-01 | — | — | WO | disclosed |
| EP-1068215-A1 | AZT DERIVATIVES EXHIBITING SPERMICIDAL AND ANTI-VIRAL ACTIVITY | Parker Hughes Institute (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-1045897-A1 | ENZYME CATALYZED THERAPEUTIC AGENTS | Newbiotics Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1045897-A4 | ENZYME CATALYZED THERAPEUTIC AGENTS | NEWBIOTICS INC (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
| WO-1999048902-A1 | AZT DERIVATIVES EXHIBITING SPERMICIDAL AND ANTI-VIRAL ACTIVITY | PARKER HUGHES INSTITUTE (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999037753-A1 | ENZYME CATALYZED THERAPEUTIC AGENTS | NEWBIOTICS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022600-A1 | AZT DERIVATIVES EXHIBITING SPERMICIDAL AND ANTI-VIRAL ACTIVITY | TYMP, DUT, UNG | CA12 4874/4885CA1 4694/4885CA2 4781/4885 |
| US-20020025922-A1 | AZT derivatives exhibiting spermicidal and anti-viral activity | TYMP, DUT, UNG | CA12 4874/4885CA1 4694/4885CA2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.